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ABSTRACT 
Background: Pyrazole and its derivatives are an important class of 
compounds and attracted widespread attention due to their pharmacological 
properties, being reported to have a large spectrum of biological effects, 
especially analgesic and anti-inflammatory properties. 
Objectives: The objectives of the present study were to screen four synthetic 
pyrazolyl derivatives (TPD compounds) for analgesic activity and select the 
best active one(s) for further biological investigations compared to the 
standard drug, these include: 
Investigation of the anti-inflammatory activity of the most active selected 
compound(s), using in vitro and in vivo techniques. In addition, possible 
ulcerogenic potential on rats using in vivo techniques will be determined. 
Determination of other pharmacological effect(s) using different in vitro 
isolated preparations. 
Elucidation of the possible mechanism(s) of action underlay the most active 
compound(s).  
Materials and Methods: TPD compounds were screened for analgesic 
activity by tail flick method in albino mice at the dose of 0.5, 1 and 2 mg/kg, 
i.p. (intraperitoneally), then TPD-04 was investigated for further  in vivo anti-
inflammatory activity by carrageenan induced rat paw edema in Wistar rats at 
 xiv  
the dose of 10, 20 and 40 mg/kg, i.p. (intraperitoneally), and in vitro anti-
inflammatory activity was evaluated using albumin denaturation, and Heat-
induced hemolysis at doses ranging from [9×102 to 9×10-1 µg/ml]. Then, the 
ulcerogenecity of TPD-04 was addressed by in vivo modelling in Wistar rats 
at the dose of 50, 100 and 200 mg/kg, PO (Per Oral); ulcer Index, severity 
Index, and % of total ulceration were measured. 
Diclofenac sodium was used as a standard drug for the study of analgesic and 
anti-inflammatory activity as well as ulcerogenecity. 
For isolated tissue; the cumulative dose-response curves of the TPD-04, 
Acetylcholine and Serotonin were constructed using different doses ranged 
 (10-8 to 10-3 M), alone and in the presence of a single dose of a blocker, then 
the values of EC50, Emax and pA2 were determined as mean ± S.E.M and 
compared statistically.  Non-selective blockers, Atropine and Cyproheptadine 
were used to elucidate the exact mechanism mediating the contractile effect 
of TPD-04. 
The statistical differences will consider to be significant if . 
Results: The tail flick method results showed that TPD compounds have 
significantly reduced pain. TPD-04 significantly reduced pain (p= 0.0003), 
when compared with control and gives maximum tail flick latency (= 6.91, 
 xv  
6.25 and 6.04) seconds at dose of [0.5, 1, and 2 mg/kg] respectively, while 
standard Diclofenac sodium(1mg/kg) give latency with (= 5.06 second).  
The carrageenan induced paw edema results showed that TPD-04 has 
significantly reduced inflammation (p=0.0103), it gives maximum percent of 
inhibition at time 3 = (28.6 % and 25.0 % for TPD-04 at [40mg/kg] and 
Diclofenac [20mg/kg], respectively), with significant value (p=0.0307). 
The percentage of membrane stabilization for TPD-04 and Diclofenac sodium 
were done at different concentrations. Maximum inhibition was observed for 
both TPD-
respectively). 
Both, the tested compound TPD-04 and the standard Diclofenac showed the 
%, respectively). 
The ulcerogenecity results revealed the advantageously high gastric tolerance 
to compounds TPD-04 compared to standard Diclofenac. 
For isolated tissue; our results revealed that TPD-04 exhibited dose-dependent 
contraction (p=0.018) on isolated rabbit intestine in vitro with lower potency 
and lower efficacy (almost its quarter effect) comparable to standards ACH 
and 5HT, this effect is mediated by muscarinic receptors and little 
serotoninergic. 
 xvi  
Conclusion: The results obtained demonstrated that TPD-04 has potential 
health benefits as promising analgesic and anti-inflammatory, with low 
ulcerogenic potential, which can be used for the treatment of various diseases 
such as cancer, neurological disorders and inflammatory disorders. 
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